BeStock  
Stocks › ABUS

Arbutus Biopharma ABUS

US equityMarket cap rank #3391
$4.09 −$0.20 (-4.66%)
Market open · Oct 8, 10:50 am ET · After hours $4.30 +0.23%
Open$4.22
Prev close$4.29
Day range$4.09 – $4.30
Volume1.09M
Market cap$810.25M
P/E (TTM)5.2
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

Community Sentiment on ABUS

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on ABUS.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

ABUS at a glance

ABUS is priced at $4.09 right now, down 4.66% on the session. That puts its market value at $810.25M, 3391st largest among the 3753 stocks we cover.

The 52-week range is $3.50 to $5.45. Today's price is about 30% of the way from the low to the high. Holders are behind 2.2% over twelve months, and down 20.4% across the last three months.

On the chart it has slipped under both the 50-day ($4.84) and 200-day ($4.54) moving averages; RSI is 30, and the last 30 sessions moved at roughly 31% annualized volatility.

Revenue for the quarter ended Jun 2026 was $1.01M, down 90.6% from a year earlier, and a net loss of $5.14M.

Valuation works out to 5.2 times trailing earnings.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

BeStock Grade

F
BeStock Grade

Composite of 2 factors below, ranked against the 3752 U.S. stocks BeStock covers.

F
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

D
Momentum

Trading closer to its 52-week high than most peers scores higher.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

ABUS is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Morningstar fair value$3.69Price is above fair value

Morningstar’s fair value model puts the stock at $3.69, so shares trade 10.8% above that estimate. On earnings multiple, it sits in the 95th percentile of its own five-year valuation range (pricier than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-4.7%
1 week
-14.4%
1 month
-21.0%
3 months
-20.4%
6 months
-6.6%
Year to date
-15.0%
1 year
-2.2%
Day range
$4.09$4.30
52-week range
$3.50$5.45

Technical signals

Full technicals →
Trend readStrong downtrend

1 bullish · 5 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-15.6%Bearish
Price vs 50-day average-15.5%Bearish
Price vs 200-day average-9.9%Bearish
50-day vs 200-day50d above 200dBullish
RSI (14)30.3Bearish
MACD (12,26,9)-0.13Bearish
Bollinger band position-26%Neutral

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

Key statistics

Bid / Ask$4.09 / $4.10
Average price today$4.16
Volume1.09MAvg (90d) 4.06M
Turnover$4.53M
Turnover rate0.89%of shares outstanding
Volume ratio0.60vs. recent average pace
Day amplitude4.90%
Market cap$810.25M
Float market cap$501.52M
Shares outstanding122.62M
EPS (TTM)-$0.17
P/E (TTM)5.18
P/B3.13
Book value / share$1.31
Earnings yield0.60%
Net profit (TTM)-$33.68M
Net assets$258.73M
30-day volatility31.2%annualized
Avg daily range (ATR)4.45%of price, 14 days
Max drawdown (1y)-25.9%-21.6% from 1y peak

Quote as of Oct 8, 2026 10:50 am ET. Prices can lag the live tape. This is background information, not a recommendation.

How ABUS ranks on BeStock

Market value#3390 of 3752
Closeness to 52-week high#2104 of 3743
Dollar volume today#1606 of 3752

Ranks are among the 3,752 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

ABUS stock: common questions

What is ABUS's latest share price?

$4.09 is the latest print for ABUS, a move of -4.66% against yesterday's close of $4.29. Today's low and high so far: $4.09 and $4.30.

How big is Arbutus Biopharma?

Equity value comes to $810.25M at the current price. By that measure it is number 3391 of the 3753 names in our coverage.

What multiple of earnings does ABUS sell for?

Buyers pay 5.2 times the last twelve months of profit (EPS $-0.17).

What's the 52-week trading range for Arbutus Biopharma?

The year's floor is $3.50 and the ceiling $5.45. Shares are 25.0% away from that ceiling.

What's the dividend situation for ABUS?

Our data shows no dividend paid by Arbutus Biopharma over the trailing twelve months.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on ABUS.

Leave a comment

Scroll to Top